Plateau phase in multiple myeloma: An end-point of conventional-dose chemotherapy

Haematologica

Volumn 84, Issue 4, 1999, Pages 336-341

  Corso, Alessandro ^a   Nozza, Andrea ^b   Lazzarino, Mario ^b   Klersy, Catherine ^a   Zappasodi, Patrizia ^b   Arcaini, Luca ^b   Bernasconi, Carlo ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Policlinico San Matteo ^*

Author keywords

Conventional therapy; Multiple myeloma; Plateau phase

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; INTERFERON; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0032863746     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Oken MM, Tslatis A, Abramson N, et al. Evaluation of intensive (VBMCP) vs standard (MP) therapy for multiple myeloma. Proc Am Soc Clin Oncol 1987; 6:203-8.
2. Salmon SE, Haut A, Bonnet. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1983; 1:453-61.
3. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-42.
4. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330:484-9.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
6. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.
7. Patriarca F, Fanin R, Silvestri F, Damiani D, Baccarani M. Autologous stem cell transplantation in multiple myeloma: a single center experience. Haematologica 1998; 83:477-9.
8. Garthon G, Tura S, Ljungman P, et al. Allogenic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325:1267-72.
9. Bensinger WI, Buckner CD, Clift RA, et al. Phase I of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10:1492-7.
10. Durie BGM, Salmon SE. The current status and future prospects of treatment for multiple myeloma. Clin Hematol 1982; 11:181-210.
11. Chronic Leukemia-Myeloma Task Force Proposed guidelines for clinical studies. Cancer Chemother Rep 1973; 4:145-58.
12. Finnish Leukemia Group treatment of multiple myeloma with intensive five drug-combination or intermittent melphalan and prednisone; a randomized multicentre trial. Eur J Haematol 1987; 38:50-4.
13. Bladè J, Lopez-Guillermo A, Bosch F, et al. Impact of response to treatment on survival in multiple myeloma: results of a series of 243 patients. Br J Haematol 1994; 88:117-21.
14. McLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339:200-5.
15. Joshua DE. Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994; 88:667-71.
16. Joshua DE, Snowdon L, Gibson J, et al. Mechanism of the escape phase of myeloma. Blood Rev 1994; 8:13-20.
17. 3H]thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 1984; 58:689-94.
18. Joshua DE, Snowdon L, Gibson J, et al. Multiple myeloma: plateau phase revisited. Haematol Rev Commun 1991; 5:59-66.
19. Oivanen TM. Plateau phase in multiple myeloma: an analysis of long term follow-up of 432 patients. Br J Haematol 1996; 92:834-9.
20. Oivanen TM. Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. Eur J Haematol 1996; 57:247-53.
21. Durie GBM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36:842-54.
22. Schemper M, Stare J. Explained variation in survival analysis. Stat Med 1996; 15:1999-2012.
23. Salmon SE. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973: 10:129-35.
24. Durie BGM, Russel DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980; 12:65-7.
25. Alexanian R, Gehan E, Haut A, et al. Unmaintained remissions in multiple myeloma. Blood 1978: 51: 1005-11.
26. McLennan ICM, Drayson M, Dunn J. Multiple myeloma. Br Med J 1994; 308:1033-6.
27. Belch A, Shelley W, Bergsagel D, Et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57:94-9.
28. Bettini R, Tonolini M, Bernasconi M. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response. Haematologica 1998; 83:708-13.
29. Offidani M, Olivieri A, Montillo M, et al. Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. Haematologica 1998; 83: 40-7.
30. San Miguel JF, Bladé Creixenti J, García-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84:36-58.